Can a Patient's own immune cells be supercharged to fight ovarian cancer?

NCT ID NCT07720180

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial is testing whether a personalized cell therapy can help women with ovarian cancer that has returned. Doctors will remove a tumor, extract immune cells called tumor-infiltrating lymphocytes (TILs), and boost them in the lab before infusing them back into the patient. After the cell infusion, patients will receive additional drugs to support the immune response. The goal is to see if this combination can shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a personalized cell therapy made from a patient's own tumor-fighting immune cells, followed by chemotherapy and immunotherapy drugs
What this could lead to
If successful, this approach could offer a durable treatment option for women with recurrent ovarian cancer, potentially leading to long-term remission.
What could go wrong
This is an early-phase trial with only 20 participants, so results may not apply broadly. The treatment involves intensive chemotherapy and carries risks of severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medical University of South Carolina Hollings Cancer Center

    Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.